使用 SARS-CoV-2 病毒载量从基线变化的时间加权平均值来评估羟氯喹作为 COVID-19 暴露后预防和早期治疗的效果。
Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.
机构信息
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
出版信息
J Med Virol. 2022 Dec;94(12):6091-6096. doi: 10.1002/jmv.28054. Epub 2022 Aug 23.
Abstract
Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance.
摘要
两项随机对照试验表明，羟氯喹（HCQ）对 SARS-CoV-2 感染的暴露后预防或早期治疗均无临床获益。我们使用这些研究的数据计算了 SARS-CoV-2 病毒载量从基线的时间加权平均变化，并证明 HCQ 并未影响病毒清除。
相似文献
1
Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.使用 SARS-CoV-2 病毒载量从基线变化的时间加权平均值来评估羟氯喹作为 COVID-19 暴露后预防和早期治疗的效果。
J Med Virol. 2022 Dec;94(12):6091-6096. doi: 10.1002/jmv.28054. Epub 2022 Aug 23.
2
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
3
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.羟氯喹作为暴露后预防严重急性呼吸综合征冠状病毒 2 感染的药物：一项随机试验。
Ann Intern Med. 2021 Mar;174(3):344-352. doi: 10.7326/M20-6519. Epub 2020 Dec 8.
4
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病（COVID-19）后成年人暴露者预防严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的暴露后预防效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
5
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.羟氯喹在非人类灵长类动物中对抗 SARS-CoV-2 感染的应用。
Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4. Epub 2020 Jul 22.
6
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
7
Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.羟氯喹对COVID-19患者的死亡率、病毒清除率及其他临床结局的影响：一项随机对照试验的系统评价和荟萃分析
Clin Transl Sci. 2021 May;14(3):1101-1112. doi: 10.1111/cts.13001. Epub 2021 May 2.
8
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.羟氯喹对 COVID-19 非重症住院患者 SARS-CoV-2 病毒载量降低没有益处。
Braz J Microbiol. 2020 Dec;51(4):1765-1769. doi: 10.1007/s42770-020-00395-x. Epub 2020 Oct 27.
9
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.羟氯喹联合阿奇霉素早期治疗门诊轻中度 COVID-19：一项评估病毒清除率的随机、双盲、安慰剂对照临床试验。
Int J Antimicrob Agents. 2021 Nov;58(5):106428. doi: 10.1016/j.ijantimicag.2021.106428. Epub 2021 Aug 25.
10
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.在患有轻至中度疾病的临床新冠肺炎患者中，羟氯喹与病毒清除较慢有关。
Medicine (Baltimore). 2020 Dec 24;99(52):e23720. doi: 10.1097/MD.0000000000023720.
引用本文的文献
1
Balanced opioid-free anesthesia with lidocaine and esketamine versus balanced anesthesia with sufentanil for gynecological endoscopic surgery: a randomized controlled trial.利多卡因和依托咪酯复合麻醉与舒芬太尼复合麻醉用于妇科内镜手术的随机对照试验：平衡型无阿片类药物麻醉。
Sci Rep. 2024 May 23;14(1):11759. doi: 10.1038/s41598-024-62824-3.
本文引用的文献
1
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.评价瑞德西韦和羟氯喹对 COVID-19 患者病毒清除效果的随机试验。
Ann Intern Med. 2021 Sep;174(9):1261-1269. doi: 10.7326/M21-0653. Epub 2021 Jul 13.
2
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.羟氯喹啉联合或不联合阿奇霉素用于高危门诊成年患者早期严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染的治疗：一项随机临床试验。
EClinicalMedicine. 2021 Mar;33:100773. doi: 10.1016/j.eclinm.2021.100773. Epub 2021 Feb 27.
3
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
4
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.羟氯喹作为暴露后预防严重急性呼吸综合征冠状病毒 2 感染的药物：一项随机试验。
Ann Intern Med. 2021 Mar;174(3):344-352. doi: 10.7326/M20-6519. Epub 2020 Dec 8.
5
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.羟氯喹治疗轻症 2019 年冠状病毒病成人患者的随机对照临床试验。
Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081. doi: 10.1093/cid/ciaa1009.
6
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.羟氯喹治疗非住院的 COVID-19 轻症成年患者：一项随机试验。
Ann Intern Med. 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16.
7
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒 2 病毒载量对 2019 年冠状病毒病住院患者插管和死亡率风险的影响。
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205. doi: 10.1093/cid/ciaa851.
8
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.法国马赛接受羟氯喹/阿奇霉素和其他方案治疗的 3737 例 COVID-19 患者的结局：一项回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101791. doi: 10.1016/j.tmaid.2020.101791. Epub 2020 Jun 25.
9
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
10
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).综述：羟氯喹啉和氯喹啉用于治疗严重急性呼吸综合征冠状病毒2（COVID-19）
Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.
Zotero 插件